Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic colorectal cancer
Suspended
 
Status Suspended
Process STA 2018
ID number 1298

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 July 2018 Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab for treating metastatic colorectal cancer after 2 therapies. However, the company have advised that the Phase III IMblaze370 trial has failed to reach its primary end point in showing an improvement in overall survival compared to regorafenib and they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes
01 June 2018 Suspended, Suspended
26 April 2018 - 25 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 May 2018 The National Institute for Health and Care Excellence has been asked to conduct an appraisal of atezolizumab for treating locally advanced or metastatic colorectal cancer after 2 therapies We have recently invited stakeholders to respond to a written consultation on the draft scope for this topic. The company that market atezolizumab have shared confidential information with NICE, in light of this information NICE will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will stop. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email on michelle.adhemar@nice.org.uk
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance